Form 4: Director Paul Schimmel Increases Stake in aTyr Pharma

Director Paul Schimmel purchased 100,000 shares of aTyr Pharma, Inc. common stock at a weighted average price of $0.4963.

Summary

• Director Paul Schimmel acquired 100,000 shares of aTyr Pharma (ATYR) common stock on May 27, 2026.
• The shares were purchased at a weighted average price of $0.4963 per share, with a price range of $0.4907 to $0.50.
• Following this transaction, the reporting person holds 779,143 shares indirectly through the Schimmel Revocable Trust and 1,413,023 shares indirectly through the Paul Schimmel Prototype PSP.
• The reporting person maintains a direct holding of 8,890 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as director-level insider buying typically indicates confidence in the company's long-term prospects.

Positives

• Insider confidence is demonstrated by a director increasing their equity position in the company.
• The purchase was made at market prices, signaling alignment between the director and shareholder interests.

Negatives

• The purchase price reflects a low valuation for the company's common stock.

Risks

• The company's stock price is trading at a low level, which may indicate market concerns regarding future growth or capital requirements.

Future Outlook

No specific forward-looking guidance was provided in this filing, as it is a standard disclosure of insider ownership changes.

Industry Context

StockSavvy.ai notes that insider buying in small-cap biotechnology firms is often viewed as a positive signal of management's belief in the underlying clinical pipeline or valuation, despite broader sector volatility.

Comparison to Industry Standards

• Insider buying is a common practice among biotech directors to signal confidence during periods of market undervaluation.
• The transaction size is consistent with typical director-level equity accumulation in small-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may interpret this purchase as a sign of stability and confidence from company leadership.

Next Steps

• Continued monitoring of insider trading activity for further accumulation or divestment.

Key Dates

Keywords

aTyr Pharma, ATYR, Insider Trading, Form 4, Biotech, Director Purchase